Sexually dimorphic tumor suppression by small mitochondrial  Arf

Jolieke G. van Oosterwijk; Heather Tillman; Charles J. Sherr

doi:10.18632/oncotarget.26651

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Priority Research Perspective:

Sexually dimorphic tumor suppression by small mitochondrial Arf

Jolieke G. van Oosterwijk, Heather Tillman and Charles J. Sherr _

PDF | Full Text | How to cite

Oncotarget. 2019; 10:1235-1237. https://doi.org/10.18632/oncotarget.26651

Metrics: PDF 1184 views | Full Text 1381 views | ?

Abstract

Jolieke G. van Oosterwijk1,3, Heather Tillman2 and Charles J. Sherr1,3

1 Department of Tumor Cell Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA

2 Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA

3 Howard Hughes Medical Institute, St. Jude Children’s Research Hospital, Memphis, TN, USA

Correspondence to:

Charles J. Sherr, email: [email protected]

Keywords: Arf tumor suppressor; small mitochondrial Arf (smArf); smArf sexual dimorphism

Received: January 02, 2019 Accepted: January 21, 2019 Published: February 08, 2019

Abstract

Internal translational initiation of the mRNA encoding the Arf tumor suppressor yields an N-terminally truncated small Arf protein (smArf) that lacks amino acid residues required for Mdm2 binding and p53 activation. Here, we report that female, but not male, mice engineered to produce only smArf in lieu of the full-length Arf protein retain residual, sexually dimorphic tumor suppressive activity.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26651

Publication Alerts

Priority Research Perspective:

Sexually dimorphic tumor suppression by small mitochondrial Arf

Abstract